< BACK COMPANY PROFILE Meet Castle Creek Biosciences. HQ: Exton, PA Leadership: Jeffrey Aronin, John Maslowski Website: castlecreekbio.com Opportunity: To help patients with skin and connective tissue conditions by creating localized gene therapies that are compatible with the unique biology of each patient and have the potential to address not only symptoms, but the underlying cause of disease. Vision: Leverage proprietary technology and manufacturing experience to deliver transformative gene therapies and improve the lives of patients suffering from rare diseases with high unmet medical needs. Status: Active QUICK FACTS > First partnered with Valor in 2015. > Completed the transformational acquisition of Fibrocell Science in December 2019, creating a gene therapy focused platform with a diverse development pipeline of three complementary clinical stage products. > Lead development program is a gene therapy for recessive dystrophic epidermolysis bullosa, a rare and incurable condition that usually begins in infancy and makes the skin incredibly fragile, leading to blistering or skin loss at the slightest friction. It is progressive and incredibly painful. > There are currently no FDA-approved treatments for any form of epidermolysis bullosa. Palliative care is the standard treatment, consisting of wound care and pain management — expensive and ineffective options that create significant financial and quality of life burdens for patients and their families. GET THE LATEST ON CASTLE CREEK BIOSCIENCES. CASTLE CREEK BIOSCIENCES NEWS WORK AT CASTLE CREEK BIOSCIENCES. CURRENT OPENINGS CONTACT OFFICES ABOUT TEAM GROWTH INVESTMENTS EARLY STAGE VALOR SIREN VENTURES VSV INVESTMENTS INVESTORS TERMS AND CONDITIONS EMAIL DISCLAIMER PRIVACY POLICY © 2021 Valor Equity Partners | All Rights Reserved By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively. OK